Table 3 Baseline characteristics of patients based on NPS group

Gender

0.000

 Male

74 (55.64%)

29 (82.86%)

34 (52.31%)

11 (33.30%)

 Female

59 (44.36%)

6 (17.14%)

31 (47.69%)

22 (66.70%)

Age

0.432

 < 18 years

41 (30.83%)

8 (22.86%)

23 (35.38%)

10 (30.30%)

 ≥ 18 years

92 (69.17%)

27 (77.14%)

42 (64.62%)

23 (69.70%)

Tumor location

0.009

 Extremities

108 (81.20%)

33 (94.28%)

46 (70.77%)

29 (87.87%)

 Non-extremities

25 (18.8%)

2 (5.72%)

19 (29.23%)

4 (12.13%)

Tumor size

0.257

 < 10.5 cm

86 (64.66%)

20 (57.14%)

41 (63.08%)

25 (75.76%)

 ≥ 10.5 cm

47 (35.34%)

15 (42.86%)

24 (36.92%)

8 (24.24%)

Histological type

0.070

 Well-differentiated

107 (80.45%)

30 (85.71%)

55 (84.62%)

22 (66.67%)

 Poorly differentiated

26 (19.55%)

5 (14.29%)

10 (15.38%)

11 (33.33%)

Enneking stage

0.000

 I/II

103 (77.44%)

31 (91.43%)

59 (90.77%)

13 (39.40%)

 III

30 (22.56%)

4 (8.57%)

6 (9.23%)

20 (60.60%)

Pathological fracture

0.005^a

 No

123 (92.48%)

34 (97.14%)

63 (96.23%)

26 (78.79%)

 Yes

10 (7.52%)

1 (2.86%)

2 (3.77%)

7 (21.21%)

Local recurrence

0.000^a

 No

119 (89.47%)

35 (100%)

64 (98.46%)

20 (60.60%)

 Yes

14 (10.53%)

0 (0%)

1 (1.54%)

13 (39.40%)

Metastasis

0.003^a

 No

123 (92.48%)

35 (100%)

62 (95.38%)

26 (78.79%)

 Yes

10 (7.52%)

0 (0%)

3 (4.62%)

7 (21.21%)

Neoadjuvant CT

0.228

 No

93 (69.92%)

23 (65.71%)

43 (66.15%)

27 (81.82%)

 Yes

40 (30.08%)

12 (34.29%)

22 (33.85%)

6 (18.18%)